GO
Loading...

ImmunoGen CEO: Toxicity is a normal course for drug development

Wednesday, 14 Aug 2013 | 6:45 PM ET

ImmunoGen president and CEO Daniel Junius discusses the potential for its cancer treatment Kadcyla, and whether investors should be concerned about toxicity problems in some of its drug trials.